|
1.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 -  10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
2.
|
|
19 p, 837.6 KB |
Malignant bone tumors (other than Ewing's) : clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
/
Redondo, Andrés (Hospital Universitario La Paz (Madrid)) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Ortiz-Cruz, Eduardo (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez-Martin, Jose A. (Hospital 12 de Octubre (Madrid)) ;
Correa, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cruz, Josefina (Hospital Universitario de Canarias (La Laguna)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Santos, Aurelio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García del Muro, Xavier (Institut Catalá d'Oncologia Hospitalet) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. [...]
2017 - 10.1007/s00280-017-3436-0
Cancer Chemotherapy and Pharmacology, Vol. 80 Núm. 6 (january 2017) , p. 1113-1131
|
|
|
3.
|
|
8 p, 535.7 KB |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
/
Joensuu, Heikki (Helsinki University Hospital) ;
Blay, Jean-Yves (University Claude Bernard Lyon I) ;
Comandone, Alessandro (Gradenigo Hospital) ;
Martin-Broto, Javier (Hosp o Virgen del Rocío (Sevilla, Andalusia)) ;
Fumagalli, Elena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Del Muro, Xavier Garcia (Hospital Universitari de Bellvitge) ;
Adenis, Antoine (Centre Oscar Lambret) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Bouche, Olivier (University Hospital Robert Debre) ;
Italiano, Antoine (Comprehensive Cancer Centre. 2Institut Bergonie) ;
Bauer, Sebastian (University of Duisburg- Essen) ;
Barone, Carlo (University Hospital A. Gemelli) ;
Weiss, Claudia (Novartis Pharma GmbH) ;
Crippa, Stefania (Novartis Farma) ;
Camozzi, Maura (Novartis Farma) ;
Castellana, Ramon (Novartis Farmaceutica SA) ;
Le Cesne, Axel (Gustave Roussy) ;
Universitat Autònoma de Barcelona
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. [...]
2017 - 10.1038/bjc.2017.290
British Journal of Cancer, Vol. 117 Núm. 9 (2017) , p. 1278-1285
|
|
|
4.
|
|
12 p, 1.3 MB |
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
/
Serrano, Cesar (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Quiroga, Sergi (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Hospital Universitari Vall d'Hebron) ;
Castro, Sandra (Hospital Universitari Vall d'Hebron) ;
Dopazo, Cristina (Hospital Universitari Vall d'Hebron) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili Manrique, Anna Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Menso, Maria M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Martín-Broto, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sansó, Miriam (Vall d'Hebron Institut d'Oncologia) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Rosell Aluja, Jordi 1955- (Vall d'Hebron Institut d'Oncologia) ;
Fletcher, J.A. (Harvard Medical School) ;
George, S. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Carles, Joan (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. [...]
2020 - 10.1186/s12885-020-6597-x
BMC Cancer, Vol. 20 Núm. 1 (may 2020) , p. 99
|
|
|
5.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
6.
|
|
11 p, 765.0 KB |
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
/
Martin-Broto, Javier (Universidad Autónoma de Madrid) ;
Redondo, Andres (Hospital Universitario La Paz (Madrid)) ;
Moura, David S. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Morales, Jose Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica) ;
Gutierrez, Antonio (Hospital Universitario Son Espases. Servicio de Hematología) ;
Díaz-Beveridge, Roberto (Hospital Universitari i Politècnic La Fe (València)) ;
Luna, Pablo (Hospital Universitario Son Espases. Servicio de Oncología Médica) ;
Martinez-Marin, Virginia (Hospital Universitario La Paz (Madrid)) ;
Marcilla, David (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Arribas, Ivan (Universitat de València) ;
Ledesma, Patricio (Sofpromed Investigacion Clinica SLU) ;
Lopez-Martin, Jose A. (Hospital Universitario 12 de Octubre (Madrid)) ;
Di Lernia, Davide (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Zamora, Jorge (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Hindi, Nadia (Universidad Autónoma de Madrid)
Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. [...]
2022 - 10.1038/s41467-022-33975-6
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 6278
|
|
|
7.
|
|
19 p, 511.1 KB |
Uterine sarcomas : clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
/
Pérez-Fidalgo, Jose Alejandro ;
Ortega, Eugenia ;
Ponce, Jordi (Hospital Universitari de Bellvitge) ;
Redondo, Andres ;
Sevilla, Isabel ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Isern Verdum, Josep (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
De Álava, Enrique ;
Galera López, Mar ;
Marquina, Gloria ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board. [...]
2023 - 10.1177/17588359231157645
Therapeutic Advances in Medical Oncology, Vol. 15 (march 2023)
|
|
|
8.
|
|
10 p, 3.5 MB |
Machine Learning Improves Risk Stratification in Myelofibrosis : An Analysis of the Spanish Registry of Myelofibrosis
/
Mosquera-Orgueira, Adrián (Hospital Clínico Universitario (Santiago de Compostela, Espanya)) ;
Pérez-Encinas, Manuel (Hospital Clínico Universitario (Santiago de Compostela, Espanya)) ;
Hernández-Sánchez, Alberto (Hospital Clínico (Salamanca, Espanya)) ;
González-Martínez, Teresa (Hospital Clínico (Salamanca, Espanya)) ;
Arellano-Rodrigo, Eduardo (Hospital Clínic i Provincial de Barcelona) ;
Martínez-Elicegui, Javier (Hospital Clínico (Salamanca, Espanya)) ;
Villaverde-Ramiro, Ángela (Hospital Clínico (Salamanca, Espanya)) ;
Raya, José-María (Hospital Universitario de Canarias (Tenerife, Espanya)) ;
Ayala, Rosa (Hospital Universitario 12 de Octubre (Madrid)) ;
Ferrer-Marín, Francisca (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Velez, Patricia (Hospital del Mar (Barcelona, Catalunya)) ;
Mora, Elvira (Hospital Universitari i Politècnic La Fe (València)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mata-Vázquez, María-Isabel (Hospital Costa del Sol (Marbella, Espanya)) ;
García Fortes, María (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Angona, Anna (Institut Català d'Oncologia) ;
Cuevas, Beatriz (Hospital Universitario de Burgos) ;
Senín, María-Alicia (Institut Català d'Oncologia) ;
Ramírez-Payer, Angel (Hospital Universitario Central de Asturias) ;
Ramírez, María-José (Hospital General (Jerez de la Frontera, Espanya)) ;
Pérez-López, Raúl (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
González de Villambrosía, Sonia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Martínez-Valverde, Clara (Institut d'Investigació Biomèdica Sant Pau) ;
Gómez-Casares, María-Teresa (Hospital Dr Negrín (Las Palmas de Gran Canaria, Espanya)) ;
García-Hernández, Carmen (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Gasior, Mercedes (Hospital Universitario La Paz (Madrid)) ;
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya)) ;
Steegmann, Juan-Luis (Hospital de La Princesa (Madrid, Spain)) ;
Álvarez-Larrán, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Hernández Rivas, Jesús María (Hospital Clínico (Salamanca, Espanya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Universitat Autònoma de Barcelona
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. [...]
2022 - 10.1097/HS9.0000000000000818
HemaSphere, Vol. 7 (december 2022)
|
|
|
9.
|
|
10 p, 1.2 MB |
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
/
Blay, Jean-Yves (Léon Bérard Center (Lyon)) ;
Hindi, Nadia (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Bollard, Julien (Léon Bérard Center (Lyon)) ;
Aguiar Júnior, Samuel (A.C.Camargo Cancer Center (Brasil)) ;
Ángel, Martín Osvaldo (Instituto Alexander Fleming (Buenos Aires)) ;
Araya, Beatriz (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Badilla-González, Ronald (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Campos, Fernando (A.C.Camargo Cancer Center (Brasil)) ;
Caro-Sánchez, C.H.S. (Instituto Nacional de Cancerología (Tlalpan)) ;
Carvajal, B. (Fundación GIST México (Mexico)) ;
Carvajal Montoya, A. (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Casavilca-Zambrano, Sandro (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Castro-Oliden, Victor (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Chacón, Matias (Instituto Alexander Fleming (Buenos Aires)) ;
Clara, Miguel (Instituto Nacional de Cancerología (Tlaplan)) ;
Collini, Paola (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Correa Genoroso, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Costa, Felipe D. (A.C.Camargo Cancer Center (Brasil)) ;
Cuellar, M. (Fundación GIST México (Mexico)) ;
Dei Tos, Angelo (Treviso General Hospital Treviso (Padua)) ;
Dominguez Malagón, Hugo Ricardo (Instituto Nacional de Cancerología (Tlalpan)) ;
Donati, Davide Maria (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Dufresne, Armelle (Léon Bérard Center (Lyon)) ;
Eriksson, Mikael (Skane University Hospital (Lund)) ;
Farias-Loza, M. (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Fernandez, Piga (Fundación GIST (Xile)) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Frisoni, Tommaso (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Garcia-Ortega, Dorian Yarih (Instituto Nacional de Cancerología (Tlalpan)) ;
Gelderblom, Hans J (Leiden University Medical Center (Leiden)) ;
Gouin, François (Léon Bérard Center (Lyon)) ;
Gómez-Mateo, María Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Haro-Varas, Juan (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Huanca, Lourdes (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Jimenez, Natalia (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Karanian, Marie (Léon Bérard Center (Lyon)) ;
Kasper, Bernd (University of Heidelberg (Mannheim)) ;
Lopes David, B.B. (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lutter, Guido (Instituto Alexander Fleming (Buenos Aires)) ;
Martinez-Said, Héctor (Hospital Medica Sur (Mexico)) ;
Martinez-Tlahuel, Jorge Luis (Instituto Nacional de Cancerología (Tlalpan)) ;
Mello, Celso A. (A.C.Camargo Cancer Center (Brasil)) ;
Morales Pérez, José Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Moura, David S. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Nascimento, Antônio Geraldo (A.C.Camargo Cancer Center (Brasil)) ;
Ortiz-Cruz, Eduardo J. (Hospital Universitario La Paz (Madrid)) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Patel, Shreyaskumar (University of Texas MD Anderson Cancer Center (Houston)) ;
Pfluger, Yanina (Instituto Alexander Fleming (Buenos Aires)) ;
Provenzano, Salvatore (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Righi, Alberto (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Rodriguez, Andrés (Instituto Alexander Fleming (Buenos Aires)) ;
Salas, Rodrigo (Fundación GIST México (Mexico)) ;
Santos, Telma G. (A.C.Camargo Cancer Center (Brasil)) ;
Scotlandi, Katia (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Soulé, Tomás (Instituto Alexander Fleming (Buenos Aires)) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Valverde, Claudía María (Hospital Universitari Vall d'Hebron) ;
Waisberg, Federico Daniel (Instituto Alexander Fleming (Buenos Aires)) ;
Zamora Estrada, Esteban (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Martín-Broto, Javier (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
2022 - 10.1016/j.ctrv.2021.102312
Cancer Treatment Reviews, Vol. 102 (january 2022) , p. 102312
|
|
|
10.
|
|
10 p, 1.4 MB |
SELNET clinical practice guidelines for bone sarcoma
/
Blay, Jean-Yves (Léon Bérard Center (Lyon)) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Bollard, Julien (Léon Bérard Center) ;
Aguiar Júnior, Samuel (A.C.Camargo Cancer Center) ;
Ángel, Martín Osvaldo (Instituto Alexander Fleming (Buenos Aires)) ;
Araya, Beatriz (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Badilla-González, Ronald (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Campos, Fernando (A.C.Camargo Cancer Center (Brasil)) ;
CHS, Caro Sánchez (Instituto Nacional de Cancerologia (Tlalpan)) ;
Carvajal Montoya, A. (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Casavilca-Zambrano, Sandro (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Castro-Oliden, Victor (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Chacón, Matias (Instituto Alexander Fleming (Buenos Aires)) ;
Clara-Altamirano, Miguel Ángel (Instituto Nacional de Cancerologia (Tlalpan)) ;
Collini, Paola (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Correa Genoroso, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Costa, Felipe D. (A.C.Camargo Cancer Center (Brasil)) ;
Cuellar, M. (Instituto Nacional de Cancerologia (Tlalpan)) ;
Dei Tos, Angelo (Treviso General Hospital Treviso (Padua)) ;
Domínguez Malagón, Hugo Ricardo (Instituto Nacional de Cancerología (Tlalpan)) ;
Donati, Davide Maria (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Dufresne, Armelle (Léon Bérard Center (Lyon)) ;
Eriksson, Mikael (Skane University Hospital (Lund)) ;
Farias-Loza, M. (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Frisoni, Tommaso (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Garcia-Ortega, Dorian Yarih (Instituto Nacional de Cancerología (Tlalpan)) ;
Gelderblom, Hans J (Leiden University Medical Center (Leiden)) ;
Gouin, François (Léon Bérard Center (Lyon)) ;
Gómez-Mateo, María Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Haro-Varas, Juan (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Hindi, Nadia (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Huanca, Lourdes (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Jimenez, Natalia (Hospital San Vicente de Paúl (Heredia)) ;
Karanian, Marie (Léon Bérard Center (Lyon)) ;
Kasper, Bernd (University of Heidelberg (Mannheim)) ;
Lopes, Artur (A.C.Camargo Cancer Center (Brasil)) ;
Lopes David, B.B. (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lutter, Guido (Instituto Alexander Fleming (Buenos Aires)) ;
Maki, Robert G. (University of Pennsylvania (New York)) ;
Martinez-Said, Héctor (Hospital Medica Sur (Mexico)) ;
Martinez-Tlahuel, Jorge Luis (Instituto Nacional de Cancerología (Tlalpan)) ;
Mello, Celso A. (A.C.Camargo Cancer Center (Brasil)) ;
Morales Pérez, José Manuel (Hospital Medica Sur (Mexico)) ;
Moura, David S. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Nakagawa, Suely Akiko (A.C.Camargo Cancer Center (Brasil)) ;
Nascimento, Antônio Geraldo (A.C.Camargo Cancer Center (Brasil)) ;
Ortiz-Cruz, Eduardo J. (Hospital Universitario La Paz (Madrid)) ;
Patel, Shreyaskumar (University of Texas MD Anderson Cancer Center (Houston)) ;
Pfluger, Yanina (Instituto Alexander Fleming (Buenos Aires)) ;
Provenzano, Salvatore (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Righi, Alberto (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Rodriguez, Andrés (Instituto Alexander Fleming (Buenos Aires)) ;
Santos, Telma G. (A.C.Camargo Cancer Center (Brasil)) ;
Scotlandi, Katia (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
MLG, Silva (A.C.Camargo Cancer Center (Brasil)) ;
Soulé, Tomás (Instituto Alexander Fleming (Buenos Aires)) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Valverde, Claudia María (Hospital Universitari Vall d'Hebron) ;
Waisberg, Federico Daniel (Instituto Alexander Fleming (Buenos Aires)) ;
Zamora Estrada, Esteban (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Martín-Broto, Javier (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Bone sarcoma are infrequent diseases, representing < 0. 2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. [...]
2022 - 10.1016/j.critrevonc.2022.103685
Critical Reviews in Oncology/Hematology, Vol. 174 (june 2022) , p. 103685
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
